drugset / Trial / NCT06632938
A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese Volunteers
RandomizedSequentialSingle-blindTreatment
Summary
The main objectives of this study are to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of single subcutaneous (SC) and intravenous (IV) doses of ABBV-382 in healthy adult Chinese volunteers.
Timeline
- Start
- 2024-10-08
- Primary completion
- 2025-05-15
- Completion
- 2025-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trosunilimab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.